Piper Sandler Maintains Overweight on Oscar Health, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan maintains an Overweight rating on Oscar Health (NYSE:OSCR) and raises the price target from $25 to $28.
August 08, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Jessica Tassan maintains an Overweight rating on Oscar Health and raises the price target from $25 to $28.
The Overweight rating and increased price target from a reputable analyst at Piper Sandler is likely to boost investor confidence in Oscar Health, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100